Alterity Therapeutics (ASX:ATH) CEO Dr. David Stamler talked with Proactive’s Tylah Tully about the company’s advancements in therapies for neurodegenerative diseases, with a focus on multiple system atrophy (MSA).
Dr. Stamler outlined the unique mechanism of action of their lead drug, which targets excess iron in the brain to address neurodegeneration.
He emphasised the importance of early intervention, highlighting results from the company’s open-label study, where 30% of late-stage MSA patients showed neurological improvement.
“What we showed is that in those patients that responded, they actually had stabilisation of biomarkers,” said Dr. Stamler.
Alterity anticipates data from its pivotal Phase 2 trial early next year, with plans to explore accelerated approval pathways or move into Phase 3 trials.
The potential market for the drug is significant, with over 15,000 MSA patients in the US alone, and projected peak sales exceeding $1 billion USD.
Dr. Stamler also shared insights into expanding the drug’s application to other conditions, including Parkinson’s disease and Friedrich’s ataxia.
#ProactiveInvestors #AlterityTherapeutics #ASX #MSATreatment #NeurodegenerativeDiseases #BiotechInnovation #HealthcareResearch #RareDiseases #ParkinsonianDisorders #FriedrichsAtaxia #ClinicalTrials #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews